Posted by Michael Wonder on 28 Aug 2017
Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
28 August 2017 - 20% reduction in disease progression vs anastrozole, a current standard treatment option.
AstraZeneca today announced that the US FDA has approved Faslodex (fulvestrant) 500 mg as monotherapy for expanded use in women with hormone-receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy.
The FDA approval is based on data from the Phase III FALCON trial, which were published in the November 2016 issue of The Lancet.
